Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12606000193572
ACTRN12606000193572
Not yet recruiting
Phase 4

Effect of Spironolactone on myocardial fibrosis and myocardial function in patients with left ventricular diastolic dysfunction.

The Alfred Hospital0 sites40 target enrollmentMay 24, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiastolic dysfunctionMyocardial fibrosis after heart transplantationCardiovascular - Other cardiovascular diseases

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Diastolic dysfunction
Sponsor
The Alfred Hospital
Enrollment
40
Status
Not yet recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 24, 2006
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
The Alfred Hospital

Eligibility Criteria

Inclusion Criteria

  • •More than 12 months after heart transplantation. Left ventricular diastolic dysfunction, LVEF \> 50%.

Exclusion Criteria

  • •Allergy to or previous therapy with spironolactone.Abnormal left ventricular systolic function, LVEF \< 50% or regional wall motion abnormality.Pregnancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Spironolactone in Adult Congenital Heart DiseaseCongenital Heart DiseaseHeart FailureEndomyocardial Fibrosis
NCT01069510Oregon Health and Science University40
Completed
Not Applicable
Hemodynamic Effects of Spironolactone in Patients With Heart FailureCongestive Heart Failure
NCT00860340University of Toledo Health Science Campus18
Completed
Phase 4
Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in CirrhosisCirrhosisPortal Hypertension
NCT02907749Changqing Yang96
Recruiting
Phase 3
SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone compared to placebo on the composite endpoint of recurrent heart failure hospitalizations and cardiovascular death in patients with heart failure with mid- range or preserved ejection fractioHeart failure with preserved or mid-range ejection fractionHFmrEF and HFpEF10019280
NL-OMON54576Charité Universitätsmedizin Berlin100
Active, not recruiting
Phase 1
SPIRonolactone In the Treatment of Heart FailureHeart Failure (i.e. Heart Failure with mid-range/ moderately reduced ejection fraction (LVEF 40- 49 %) or with preserved ejection fraction (LVEF = 50 %) with evidence of impaired left ventricular filling capabilities)/ HFmrEF and HFpEFTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2017-000697-11-DECharité Universitätsmedizin Berlin1,300